Literature DB >> 8013512

Study of low dosage prostaglandin--usages and complications.

G K Singh1, L V Fong, A P Salmon, B R Keeton.   

Abstract

Low dosage intravenous (< 0.01 micrograms.kg-1.min-1) and oral prostaglandin E have been reported to produce fewer complications than higher intravenous doses in the ductal manipulation of congenital heart disease. Over a 3-year period 34 patients were treated with low dosage intravenous or oral prostaglandin. Eighteen (53%) had complications associated with this treatment with 14 having more than one complication. Major complications occurred in nine neonates: necrotising enterocolitis (7), apnoea/bradycardia (5), convulsions (1), haemorrhage (1), and resulted in a change of management. This study therefore concludes that the high incidence of complications is similar with both low and high dosages of intravenous and oral prostaglandin. The use of prostaglandin in any form deserves caution.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8013512     DOI: 10.1093/oxfordjournals.eurheartj.a060506

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  9 in total

1.  Transcriptional profiling reveals ductus arteriosus-specific genes that regulate vascular tone.

Authors:  Elaine L Shelton; Gerren Ector; Cristi L Galindo; Christopher W Hooper; Naoko Brown; Irene Wilkerson; Elise R Pfaltzgraff; Bibhash C Paria; Robert B Cotton; Jason Z Stoller; Jeff Reese
Journal:  Physiol Genomics       Date:  2014-05-01       Impact factor: 3.107

2.  Do predictors exist for a successful withdrawal of preoperative prostaglandin E(1) from neonates with d-transposition of the great arteries and intact ventricular septum?

Authors:  Angela Oxenius; Maja I Hug; Ali Dodge-Khatami; Anna Cavigelli-Brunner; Urs Bauersfeld; Christian Balmer
Journal:  Pediatr Cardiol       Date:  2010-10-01       Impact factor: 1.655

3.  Transporting newborn infants with suspected duct dependent congenital heart disease on low-dose prostaglandin E1 without routine mechanical ventilation.

Authors:  Kathryn A Browning Carmo; Peter Barr; Maureen West; Neil W Hopper; Jennifer P White; Nadia Badawi
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2006-08-11       Impact factor: 5.747

4.  cAMP-dependent reversal of opioid- and prostaglandin-mediated depression of the isolated respiratory network in newborn rats.

Authors:  K Ballanyi; P M Lalley; B Hoch; D W Richter
Journal:  J Physiol       Date:  1997-10-01       Impact factor: 5.182

5.  Elevated NCX1 and NCKX4 expression in the patent postnatal ductus arteriosus of ductal-dependent congenital heart disease patients.

Authors:  Haifa Hong; Yu Xia; Yanjun Sun; Lincai Ye; Jinfen Liu; Jie Bai; Haibo Zhang
Journal:  Pediatr Cardiol       Date:  2014-12-12       Impact factor: 1.655

6.  Neonatal patent ductus arteriosus recanalization and stenting in critical Ebstein's anomaly.

Authors:  G Santoro; M T Palladino; M G Russo; R Calabrò
Journal:  Pediatr Cardiol       Date:  2007-09-15       Impact factor: 1.655

7.  Hypoxia-induced cytosolic calcium decrease is mediated primarily by the forward mode of Na(+)/Ca(2+) exchanger in smooth muscle cells of fetal ductus arteriosus.

Authors:  Haifa Hong; Huiwen Chen; Wei Gao; Xiaoman Cai; Yanjuan Sun; Meng Yin; Jinfen Liu
Journal:  Pediatr Cardiol       Date:  2009-06-04       Impact factor: 1.655

8.  Evaluation of low dose prostaglandin E1 treatment for ductus dependent congenital heart disease.

Authors:  H H Kramer; M Sommer; S Rammos; O Krogmann
Journal:  Eur J Pediatr       Date:  1995-09       Impact factor: 3.183

9.  The induced prostaglandin E2 pathway is a key regulator of the respiratory response to infection and hypoxia in neonates.

Authors:  Annika O Hofstetter; Sipra Saha; Veronica Siljehav; Per-Johan Jakobsson; Eric Herlenius
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-29       Impact factor: 11.205

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.